SCHEMBL6464772

SCHEMBL6464772

CN(C)c1cc(NC2CCC(CNC(=O)Nc3c(Cl)cccc3C(F)(F)F)CC2)nc2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 9/20 0.41
NPY5R Q15761 7/20 0.41
ADRA2A P08913 7/20 0.41
ACP1 P24666 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38
MELK Q14680 1/20 0.36
POLB P06746 1/20 0.36
EPHX2 P34913 1/20 0.36
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
PTGS2 P35354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6459092 1.00 MCHR1 (0.41) MCHR1NPY5RADRA2AACP1L3MBTL1
SCHEMBL6868239 0.93 NPY5R (0.43) MCHR1NPY5RADRA2AACACBACACA
SCHEMBL6868236 0.93 NPY5R (0.43) MCHR1NPY5RADRA2AACACBACACA
SCHEMBL6877053 0.90 KDR (0.42) MCHR1NPY5RADRA2AACACBACACA
SCHEMBL6877062 0.90 KDR (0.42) MCHR1NPY5RADRA2AACACBACACA
SCHEMBL6868474 0.90 MCHR1 (0.44) MCHR1NPY5RADRA2AACP1L3MBTL1
SCHEMBL6868480 0.90 MCHR1 (0.44) MCHR1NPY5RADRA2AACP1L3MBTL1
SCHEMBL6867920 0.90 ACP1 (0.44) MCHR1NPY5RADRA2AACP1POLB
SCHEMBL6867914 0.90 ACP1 (0.44) MCHR1NPY5RADRA2AACP1POLB
SCHEMBL6879539 0.88 NPY5R (0.43) MCHR1NPY5RADRA2AACP1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 MCHR1 2/4885NPY5R 8/4885ADRA2A 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.